Article

Laser may be better than corticosteroids for treating diabetic macular edema

When treating diabetic macular edema (DME), the conventional laser treatment may be more effective than the newer drug therapy used to treat abnormal swelling around the eye, according to a National Eye Institute (NEI) study.

Bethesda, MD-When treating diabetic macular edema (DME), the conventional laser treatment may be more effective than the newer drug therapy used to treat abnormal swelling around the eye, according to a National Eye Institute (NEI) study.

For long-term treatment of DME, laser therapy is more effective than corticosteroids and has fewer side effects, according to the study published in the July edition of Ophthalmology.

Said to be the first study to compare long-term benefits of both treatments and their potential side effects, there is no rationale that one corticosteroid preparation should be substantially different from another, according to study authors.

"Results of this study should confirm the use of laser treatment for DME and will have a significant impact on quality of life for tens of thousands of people being treated for DME in the United States each year," according to Paul A. Sieving, MD, PhD, director of the NEI.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.